|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | G01N 33/574 | |
| C12Q 1/68 |
| (11) | Patento numeris | 2235535 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 08859508.7 |
| Europos patento paraiškos padavimo data | 2008-12-05 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-10-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-11-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2008/013448 |
| Data | 2008-12-05 |
| (87) | Numeris | WO 2009/075797 |
| Data | 2009-06-18 |
| (30) | Numeris | Data | Šalis |
| 5806 P | 2007-12-07 | US |
| (72) |
SCHAFER, Peter, H., US
BARTLETT, Justin, B., US
ZHANG, Ling-Hua, US
|
| (73) |
CELGENE CORPORATION,
86 Morris Avenue, Summit, NJ 07901,
US
|
| (54) | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN`S LYMPHOMA |
| BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN`S LYMPHOMA |